Delving into the Latest Updates on Nanjing Huicheng Pharmaceutical Co., Ltd. with Synapse

Overview

主要目的：评价SH3765片单、多次给药在晚期恶性肿瘤患者中的安全性和耐受性，确定剂量限制性毒性（DLT）和最大耐受剂量（MTD）。次要目的：研究SH3765片的药代动力学特征；初步评估SH3765片治疗晚期恶性肿瘤患者的疗效，为确定II期临床推荐剂量提供依据。探索性目的：探索SH3765片治疗晚期恶性肿瘤患者的生物标志物。

[Translation]

Primary objective: To evaluate the safety and tolerability of single and multiple administrations of SH3765 tablets in patients with advanced malignant tumors, and to determine the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD). Secondary objective: To study the pharmacokinetic characteristics of SH3765 tablets; to preliminarily evaluate the efficacy of SH3765 tablets in the treatment of patients with advanced malignant tumors, and to provide a basis for determining the recommended dose for Phase II clinical trials. Exploratory objective: To explore biomarkers of SH3765 tablets in the treatment of patients with advanced malignant tumors.

Start Date-

Sponsor / Collaborator

Nanjing Huicheng Pharmaceutical Co., Ltd.

[+1]

100 Clinical Results associated with Nanjing Huicheng Pharmaceutical Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Nanjing Huicheng Pharmaceutical Co., Ltd.

Login to view more data

100 Deals associated with Nanjing Huicheng Pharmaceutical Co., Ltd.

Login to view more data

100 Translational Medicine associated with Nanjing Huicheng Pharmaceutical Co., Ltd.

Login to view more data